Results 51 to 60 of about 87,925 (315)

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients

Drug Design, Development and Therapy, 2022
Marwa S Hamza,1 Samia A Shouman,2 Raafat Abdelfattah,3 Heba S Moussa,4 Mervat M Omran2 1Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt; 2Pharmacology Unit, Cancer Biology ...
Hamza MS, Shouman SA, Abdelfattah R, Moussa HS, Omran MM   +4 more
doaj  

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

Pharmaceutics, 2022
The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug’s efficacy or tolerance.
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stéphane Bouchet, François-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot   +25 more
doaj   +1 more source

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

New England Journal of Medicine, 2006
BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations ...
M. Talpaz, N. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O'brien, C. Nicaise, E. Bleickardt, M. Blackwood-Chirchir, V. Iyer, Tai-Tsang Chen, F. Huang, A. DeCillis, C. Sawyers, C. Sawyers   +16 more
semanticscholar   +1 more source

Antileukemic Activity of hsa-miR-203a-5p by Limiting Glutathione Metabolism in Imatinib-Resistant K562 Cells

Current Issues in Molecular Biology, 2022
Imatinib has been the first and most successful tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), but many patients develop resistance to it after a satisfactory response. Glutathione (GSH) metabolism is thought to be one of the factors
Priyanka Singh, Radheshyam Yadav, Malkhey Verma, Ravindresh Chhabra   +3 more
doaj   +1 more source

NovoMol: Recurrent Neural Network for Orally Bioavailable Drug Design and Validation on PDGFRα Receptor [PDF]

arXiv, 2023
Longer timelines and lower success rates of drug candidates limit the productivity of clinical trials in the pharmaceutical industry. Promising de novo drug design techniques help solve this by exploring a broader chemical space, efficiently generating new molecules, and providing improved therapies.
arxiv  

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Journal of Clinical Oncology, 2017
Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy.
J. Cortes, C. Gambacorti-Passerini, M. Deininger, M. Mauro, C. Chuah, Dong-Wook Kim, I. Dyagil, N. Glushko, D. Milojkovic, P. le Coutre, V. García‐Gutiérrez, Laurence Reilly, A. Jeynes-Ellis, E. Leip, N. Bardy-Bouxin, A. Hochhaus, T. Brümmendorf   +16 more
semanticscholar   +1 more source

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

Frontiers in Pharmacology, 2020
Long-term use of imatinib is effective and well-tolerated in children with chronic myeloid leukaemia (CML) yet defining an optimal dosing regimen for imatinib in younger patients is a challenge.
Jeffry Adiwidjaja, Alan V. Boddy, Alan V. Boddy, Andrew J. McLachlan   +3 more
doaj   +1 more source

Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach [PDF]

, 2008
The evolutionary dynamics of a system of cancerous cells in a model of chronic myeloid leukemia (CML) is investigated by a statistical approach. Cancer progression is explored by applying a Monte Carlo method to simulate the stochastic behavior of cell reproduction and death in a population of blood cells which can experience genetic mutations.
arxiv   +1 more source

Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report

Biological Procedures Online, 2004
Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance.
Iqbal Zafar, Siddiqui Rubina T., Qureshi Javed A.   +2 more
doaj   +1 more source